Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases

Biochemistry

Volumn 48, Issue 2, 2009, Pages 379-387

  Bannwarth, Ludovic ^a,b   Rose, Thierry ^c   Dufau, Laure ^a   Vanderesse, Régis ^d   Dumond, Julien ^b   Jamart Grégoire, Brigitte ^d   Pannecouque, Christophe ^e   De Clercq, Erik ^e   Reboud Ravaux, Michèle ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUT PASTEUR   (France)

^d LAB DE CHIM PHYS MACROMOLECULAIRE   (France)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITES; ALKYL CHAINS; ANALYTICAL ULTRACENTRIFUGATION; D-AMINO ACIDS; DIMER DISRUPTIONS; EXPERIMENTAL EVIDENCES; HIV-1 PROTEASE; HOMODIMER; IN-VITRO; INHIBITOR COMPLEXES; INHIBITORY EFFECTS; INTERDIGITATION; KINETIC DATUM; LIPOPEPTIDE; MODE OF ACTIONS; MOLECULAR DYNAMICS SIMULATIONS; NEW SERIES; PEPTIDE MOIETIES; SEQUENCE VARIATIONS; TRI-PEPTIDES; WILD TYPES;

ALKYLATION; AMINES; AMINO ACIDS; CENTRIFUGATION; DIMERIZATION; DYNAMICS; MOLECULAR DYNAMICS; OLIGOMERS; ORGANIC ACIDS;

MONOMERS;

ALKYL GROUP; DIMER; GLUTAMIC ACID; HOMODIMER; LEUCINE; LIPOPEPTIDE; MONOMER; PALMITIC ACID DERIVATIVE; PROTEINASE; TRIPEPTIDE; TYROSINE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; PEPTIDE; PROTEINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BETA SHEET; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; DIMERIZATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIMULATION; ULTRACENTRIFUGATION; WILD TYPE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; PH; PROTEIN BINDING; PROTEIN CONFORMATION; TEMPERATURE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BINDING SITES; DIMERIZATION; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LIPOPEPTIDES; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; TEMPERATURE;

EID: 59849109511     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi801422u     Document Type: Article

References (43)

1. Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., and Sigal, I. S. (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 85, 4686-4690.
2. Peng, C., Ho, B. K., Chang, T. W., and Chang, N. T. (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63, 2550-2556.
3. Carr, A. (2003) Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2, 624-634.
4. De Clercq, E. (2004) Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2, 704-720.
5. Wells, J. A., and McClendon, C. L. (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009.
6. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B. K., Baldwin, E., Weber, I. T., Selk, L. M., Clawson, L., Schneider, J., and Kent, S. B. (1989) Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616-621.
7. Spinelli, S., Liu, Q. Z., Alzari, P. M., Hirel, P. H., and Poljak, R. J. (1991) The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 73, 1391-1396.
8. Hong, L., Hartsuck, J. A., Foundling, S., Ermolieff, J., and Tang, J. (1998) Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant. Protein Sci. 7, 300-305.
9. Hamelberg, D., and McCammon, J. A. (2005) Fast peptidyl cis-trans isomerization within the flexible Gly-rich flaps of HIV-1 protease. J. Am. Chem. Soc. 127, 13778-13779.
10. Hornak, V., Okur, A., Rizzo, R. C., and Simmerling, C. (2006) HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc. Natl. Acad. Sci. U.S.A. 103, 915-920.
11. Ding, F., Layten, M., and Simmerling, C. (2008) Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments. J. Am. Chem. Soc. 130, 7184-7185.
12. Sayer, J. M., Liu, F., Ishima, R., Weber, I. T., and Louis, J. M. (2008) Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J. Biol. Chem. 283, 13459-13470.
13. Todd, M. J., Semo, N., and Freire, E. (1998) The structural stability of the HIV-1 protease. J. Mol. Biol. 283, 475-488.
14. Zutshi, R., Franciskokovich, J., Shultz, M., Schweitzer, B., Bishop, P., Wilson, M., and Chmielewski, J. (1997) Targeting the dimer-ization interface of HIV-1 protease: inhibition with cross-linked interfacial peptides. J. Am. Chem. Soc. 119, 4841-4845.
15. Boggetto, N., and Reboud-Ravaux, M. (2002) Dimerization inhibitors of HIV-1 protease. Biol. Chem. 383, 1321-1324.
16. Bannwarth, L., and Reboud-Ravaux, M. (2007) An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface. Biochem. Soc. Trans. 35, 551-554.
17. Bowman, M. J., and Chmielewski, J. (2008) Sidechain-linked inhibitors of HIV-1 protease dimerization. Bioorg. Med. Chem. (doi: 10.1016/j.bmc.2008.02.060).
18. Findeis, M. A., and Molineaux, S. M. (1999) Design and testing of inhibitors of fibril formation. Methods Enzymol. 309, 476-488.
19. Nakagami, Y., Nishimura, S., Murasugi, T., Kaneko, I., Meguro, M., Marumoto, S., Kogen, H., Koyama, K., and Oda, T. (2002) A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br. J. Pharmacol. 137, 676-682.
20. Pinkner, J. S., Remaut, H., Buelens, F., Miller, E., Aberg, V., Pemberton, N., Hedenstrom, M., Larsson, A., Seed, P., Waksman, G., Hultgren, S. J., and Almqvist, F. (2006) Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl. Acad. Sci. U.S.A. 103, 17897-17902.
21. Schramm, H. J., Nakashima, H., Schramm, W., Wakayama, H., and Yamamoto, N. (1991) HIV-1 reproduction is inhibited by peptides derived frm the N- and C-termini of HIV-1 protease. Biochem. Biophys. Res. Commun. 179, 847-851.
22. Franciskovich, J., Houseman, K., Mueller, R., and Chmielewski, J. A. (1993) Bioorg. Med. Chem. Lett. 3, 765-768.
23. Schramm, H. J., Boetzel, J., Buttner, J., Fritsche, E., Gohring, W., Jaeger, E., Konig, S., Thumfart, O., Wenger, T., Nagel, N. E., and Schramm, W. (1996) The inhibition of human immunodeficiency virus proteases by "interface peptides". Antiviral Res. 30, 155-170.
24. Schramm, H. J., de Rosny, E., Reboud-Ravaux, M., Buttner, J., Dick, A., and Schramm, W. (1999) Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol. Chem. 380, 593-596.
25. Dumond, J., Boggetto, N., Schramm, H. J., Schramm, W., Takahashi, M., and Reboud-Ravaux, M. (2003) Thyroxine-deriva-tives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease. Biochem. Pharmacol. 65, 1097-1102.
26. Petry, H., Ast, E., De Rosny, E., Jentsch, K.-D., Hunsmann, G., Goldmann, C., Lüke, W., Büttner, J., Reboud, M., Schramm, W., and Schramm, H. J. (1999) HIV-Infekt, Springer, Paris, France.
27. Breccia, P., Boggetto, N., Perez-Fernandez, R., Van Gool, M., Takahashi, M., Rene, L., Prados, P., Badet, B., Reboud-Ravaux, M., and de Mendoza, J. (2003) Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit. J. Med. Chem. 46, 5196-5207.
28. Bouras, A., Boggetto, N., Benatalah, Z., de Rosny, E., Sicsic, S., and Reboud-Ravaux, M. (1999) Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med. Chem. 42, 957-962.
29. Merabet, N., Dumond, J., Collinet, B., Van Baelinghem, L., Boggetto, N., Ongeri, S., Ressad, F., Reboud-Ravaux, M., and Sicsic, S. (2004) New constrained "molecular tongs" designed to dissociate HIV-1 protease dimer. J. Med. Chem. 47, 6392-6400.
30. Bannwarth, L., Kessler, A., Pethe, S., Collinet, B., Merabet, N., Boggetto, N., Sicsic, S., Reboud-Ravaux, M., and Ongeri, S. (2006) Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization. J. Med. Chem. 49, 4657-4664.
31. Bowman, M. J., and Chmielewski, J. (2002) Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides. Biopolymers 66, 126-133.
32. Neimark, J., and Briand, J. P. (1993) Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. Pept. Res. 6, 219-228.
33. Ohtaka, H., Schon, A., and Freire, E. (2003) Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry 42, 13659-13666.
34. Muzammil, S., Ross, P., and Freire, E. (2003) A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42, 631-638.
35. Billich, A., Hammerschmid, F., and Winkler, G. (1990) Purification, assay and kinetic features of HIV-1 proteinase. Biol. Chem. Hoppe-Seyler 371, 265-272.
36. Szeltner, Z., and Polgar, L. (1996) Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration. J. Biol. Chem. 271, 5458-5463.
37. Zhang, Z. Y., Poorman, R. A., Maggiora, L. L., Heinrikson, R. L., and Kezdy, F. J. (1991) Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 266, 15591-15594.
38. Schuck, P. (2000) Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78, 1606-1619.
39. Lindahl, E., Azuara, C., Koehl, P., and Delarue, M. (2006) NOMAD-Ref: visualization, deformation and refinement of mac-romolecular structures based on all-atom normal mode analysis. Nucleic Acids Res. 34, W52-W56.
40. Louis, J. M., Wondrak, E. M., Kimmel, A. R., Wingfield, P. T., and Nashed, N. T. (1999) Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism. J. Biol. Chem. 274, 23437-23442.
41. Frutos, S., Rodriguez-Mias, R. A., Madurga, S., Collinet, B., Reboud-Ravaux, M., Ludevid, D., and Giralt, E. (2007) Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling. Biopolymers 88, 164-173.
42. Koh, Y., Matsumi, S., Das, D., Amano, M., Davis, D. A., Li, J., Leschenko, S., Baldridge, A., Shioda, T., Yarchoan, R., Ghosh, A. K., and Mitsuya, H. (2007) Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282, 28709-28720.
43. Muzammil, S., Armstrong, A. A., Kang, L. W., Jakalian, A., Bonneau, P. R., Schmelmer, V., Amzel, L. M., and Freire, E. (2007) Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J. Virol. 81, 5144-5154.